z-logo
Premium
Impaired Suppressive Capacity of Activation‐Induced Regulatory B Cells in Systemic Lupus Erythematosus
Author(s) -
Gao Nele,
Dresel Julia,
Eckstein Volker,
Gellert Rimma,
Störch Hannah,
Venigalla Ram K. C.,
Schwenger Vedat,
Max Regina,
Blank Norbert,
Lorenz HannsMartin,
Tretter Theresa
Publication year - 2014
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.38742
Subject(s) - cd80 , regulatory b cells , immunology , il 2 receptor , cd19 , cd40 , cytokine , immune system , t cell , biology , interleukin 21 , b cell , flow cytometry , population , interleukin 10 , cytotoxic t cell , medicine , antibody , in vitro , biochemistry , environmental health
Objective B cells with immunoregulatory properties (Breg cells) have been described in mice, but their role in the control of human immune responses is not well defined. We recently identified a human population of activated FSC high B cells that exhibited regulatory activity toward T helper cells. The aim of the present study was to test such induced Breg (iBreg) cells in patients with autoimmune disease. Methods Purified CD19+FSC high B cells derived from patients with systemic lupus erythematosus (SLE) or from healthy donors, which were activated via their B cell receptor, were cocultured with CD3‐stimulated CD4+ T helper cells from SLE patients or healthy donors. 3 H‐thymidine incorporation, flow cytometry, and enzyme‐linked immunosorbent assay (ELISA) were used to analyze proliferation, cytokine secretion, and surface marker expression. Results Although under costimulatory conditions, FSC high SLE B cells supported the proliferation of healthy donor T cells to a similar extent as donor B cells, their regulatory function was significantly diminished in B cell suppressor assays. Similar effects were seen when SLE T cells were used, confirming that SLE T cells were equally susceptible to iBreg cell signals as healthy donor T cells and that SLE iBreg cell defects were independent of T cell origin. B cell viability and expression of surface markers (CD25, CD80, and B7‐H1) or cytokines (interleukin‐6 [IL‐6], tumor necrosis factor α, and IL‐10) were comparable in the two B cell populations. There was no correlation between the extent of iBreg cell–induced inhibition and disease activity. CD19+FSC high B cells from patients with another systemic autoimmune disease, granulomatosis with polyangiitis (Wegener's) (GPA), exhibited no regulatory defects, which suggests that the iBreg cell defects were SLE‐specific and not a general consequence of autoimmunity or inflammation. Conclusion Induced Breg cells from SLE patients, but not GPA patients, are less effective in the control of T helper cell proliferation, which supports the reported skewed B cell repertoire in SLE. The malfunctioning SLE iBreg cells might allow the overstimulation of immune responses and contribute to the initiation and/or perpetuation of disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom